CD8A and neoplasm: ,6 Administration of LCMV in tumor models consistently results in prolonged immune activation over a few weeks not compromised by anti-viral immune mechanisms such as neutralizing antibodies, which potentially leads to activation of tumor-specific CD8+ T cells.